Antibiotics are among medicine’s greatest achievements. They have turned once-lethal bacterial infections into treatable illnesses and made surgery, cancer therapy and much of modern medicine possible. Yet every antibiotic prescription also carries risk. Sometimes that risk can have devastating consequences.
By Tim Sandle
Christian John Lillis knows this better than most. In 2010, his mother, Peggy Lillis, was a healthy 56-year-old kindergarten teacher when she underwent a root canal. According to her son’s account included in the new CDC Antimicrobial Resistance Threats Report, her dentist prescribed clindamycin. Four days later she developed diarrhoea. The family initially did not connect it with the antibiotic. Her condition deteriorated rapidly and, when she reached hospital, doctors diagnosed toxic megacolon caused by Clostridioides difficile, or C. diff, and septic shock. About a week after the dental procedure, she died.
That experience ultimately led Christian John Lillis and his brother to establish the Peggy Lillis Foundation, an organisation dedicated to C. diff education and advocacy. A 2025 poll commissioned by the foundation found that 54% of 1,000 US respondents remained unfamiliar with C. diff, highlighting the continuing gap between the infection's public-health importance and public recognition.
Now Christian John Lillis is bringing that patient and family perspective directly into the national conversation around antimicrobial resistance, participating in the CDC webinar Update to the Antimicrobial Resistance Threats Report: A Closer Look. His central message is deceptively simple: stewardship is not just about preserving antibiotics for the future. It is also about protecting the person receiving an antibiotic today.
What is C. diff?
Clostridioides difficile is a spore-forming bacterium capable of causing diarrhoea and inflammation of the colon. Severe disease can progress to complications including toxic megacolon, sepsis and death. Its hardy spores can also persist in the environment, facilitating transmission, particularly in healthcare settings. Its relationship with antibiotics is especially important.
The human intestine contains an extraordinarily complex microbial ecosystem. Collectively known as the gut microbiome, these microorganisms help occupy ecological niches and create what microbiologists call "colonisation resistance", making it harder for pathogens to proliferate.
Antibiotics can disturb that ecosystem. While killing the bacteria responsible for an infection, an antimicrobial can also eliminate susceptible members of the normal intestinal community. That ecological disruption can create an opportunity for C. diff to multiply and produce toxins that damage the intestinal lining.
The CDC therefore identifies recent antibiotic exposure as an important risk factor: the likelihood of developing C. diff is higher during antibiotic treatment and for up to three months afterwards.
This does not mean that taking an antibiotic inevitably causes C. diff. Most courses do not. Risk depends on the drug, duration of treatment, individual susceptibility, healthcare exposure, age and other factors. But epidemiological evidence consistently establishes antibiotic exposure as a major modifiable risk factor for infection.
A large 2023 case-control study published in Open Forum Infectious Diseases, for example, compared the risks associated with different antibiotics and described antibiotic exposure as the greatest risk factor for community-associated C. diff. Importantly, risk varied substantially between antibiotic agents.
Why clindamycin matters
Peggy Lillis' treatment is particularly relevant because the antibiotic involved was clindamycin. Clindamycin has a long-recognised association with C. diff. The CDC's current guidance for dental prescribers explicitly advises avoiding clindamycin when alternatives are available because it can cause more frequent and severe adverse effects, including C. diff infection.
This principle is also reflected in current American Dental Association antibiotic stewardship guidance. For odontogenic infections requiring systemic treatment, amoxicillin or penicillin V are listed as first-line options in appropriate patients, while clindamycin is reserved for circumstances in which alternatives such as azithromycin are unsuitable, specifically because of its high C. diff risk.
The issue goes beyond one drug, however. Cephalosporins, fluoroquinolones, co-amoxiclav and other broad-spectrum agents have also been associated with C. diff. NICE notes that no antibiotic can be entirely excluded from the risk.
A 2026 real-world analysis of 201,911 patients with C. diff further illustrates this point. Among the study population, 33.9% had recorded antibiotic exposure, with extended-spectrum penicillins, third-generation cephalosporins and aminopenicillins among the most frequently used classes shortly before diagnosis. The authors argue that stewardship therefore needs to extend across antibiotic classes rather than simply targeting historically notorious agents such as clindamycin.
A major public-health burden
C. diff is sometimes viewed primarily as a hospital infection. That picture is now incomplete. In its 2026 Antimicrobial Resistance Threats Report, the CDC estimates that there were 412,504 C. diff cases in the United States in 2023, including 223,568 classified as community-associated and 188,936 as healthcare-associated. The agency estimates 11,339 deaths among hospitalised cases and more than $6.4 billion in attributable healthcare costs.
Older adults remain particularly vulnerable. In 2023, the reported infection rate among those aged 65 and over was 351 cases per 100,000 people, compared with 75.5 per 100,000 among people under 65.
There has nevertheless been progress. The CDC previously classified C. diff as an "urgent" antimicrobial-resistance threat. Following reductions in infections since 2011, it is now classified as a serious threat. Yet the agency cautions against complacency, particularly because community-associated infections have increased slightly since the pandemic-era decline.
There is an apparent paradox here. C. diff is not primarily included in the report because it is intrinsically an antibiotic-resistant pathogen. Instead, it belongs in the antimicrobial-resistance conversation because antibiotic use and microbial transmission are forces driving both C. diff disease and antimicrobial resistance.
Reducing unnecessary antibiotic exposure can therefore produce two benefits: lowering selection pressure for resistant organisms and reducing the immediate possibility of antibiotic-associated complications such as C. diff.
Dentistry and the stewardship opportunity
Peggy Lillis' case also raises questions about antibiotic use in dentistry. Modern stewardship guidance stresses that antibiotics should not substitute for definitive dental treatment. The CDC advises dentists to prioritise procedures such as drainage, extraction, pulpotomy or root-canal treatment for most appropriate dental conditions and generally not to add an antibiotic when definitive treatment is available. Systemic antibiotics become appropriate when findings indicate spreading or systemic infection, such as fever or malaise with intraoral swelling.
The American Dental Association similarly recommends against antibiotics for most pulpal and periapical dental pain and localised swelling in immunocompetent adults when definitive dental treatment can be provided. This is what antimicrobial stewardship looks like at the individual level: first determining whether an antibiotic is actually required, then selecting an appropriate drug, dose and duration.
Crucially, stewardship is not an anti-antibiotic philosophy. The Infectious Diseases Society of America and Society for Healthcare Epidemiology of America define it as coordinated interventions to improve and measure appropriate antibiotic use, including optimisation of drug selection, dose, duration and route. Among the demonstrated benefits are reductions in adverse events, including C. diff infection. Withholding an antibiotic when one is genuinely required can itself be dangerous. The objective is therefore not simply fewer antibiotics, but better antibiotic use.
Putting patients back into antimicrobial resistance
This distinction explains why the patient voice belongs alongside microbiologists, epidemiologists and infectious-disease specialists in discussions about antimicrobial resistance. Resistance is frequently communicated through abstract measures: susceptibility percentages, resistant isolates, surveillance graphs and national estimates. These are indispensable for understanding the problem, but they can obscure what antimicrobial exposure means at the level of an individual patient and family.
Christian John Lillis's perspective provides the missing human element. The lesson from his mother's death is not that antibiotics themselves should be feared. Indeed, he has described them as "miracle drugs" underpinning modern medicine. Rather, his argument is that society must recognise their potential harms alongside their benefits if these drugs are to be used safely and remain effective. That is the deeper connection between C. diff prevention and antimicrobial resistance.
Every unnecessary prescription represents an avoidable biological intervention in a patient's microbial ecosystem. Every appropriately avoided prescription reduces an individual's exposure to potential adverse effects while also reducing antibiotic selection pressure at population level.
Peggy Lillis' death occurred in 2010, but the science that followed has made its lesson increasingly difficult to ignore. Antibiotic stewardship is not simply a strategy for conserving medicines for some hypothetical future patient. It is a patient-safety intervention for the person sitting in the dental chair, clinic or hospital today.
Key sources
- CDC: Clostridioides difficile, 2026 Antimicrobial Resistance Threats Report
- CDC: Antimicrobial Resistance Threats Reports
- CDC: Checklist for Antibiotic Prescribing in Dentistry
- American Dental Association: Antibiotic Stewardship
- Miller et al., Open Forum Infectious Diseases: antibiotic-specific risks for community-associated C. difficile
- NICE: C. difficile infection and broad-spectrum antibiotics
- IDSA/SHEA: Guidelines for Implementing an Antibiotic Stewardship Program

No comments:
Post a Comment
Pharmaceutical Microbiology Resources